AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32285449 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention interviews
Number of subjects: 30
Study 36191860 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 88
Study 36191860 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT
Number of subjects: 88
Study 36191860 — intervention group
Group type: COMPARATOR
Intervention: RMTsham
Number of subjects: 88
Study 36191860 — intervention group
Group type: COMPARATOR
Intervention: IMTsham
Number of subjects: 88
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry partner owned all data
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication constraints described
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry partner could review data during the trial
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry partner could stop the trial early without any specific reason
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear ownership of data
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear if industry partner could review data
Number of subjects: 42
Study 34454496 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication constraints not communicated to trial participants
Number of subjects: 42
Study 33734131 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with rituximab
Number of subjects: 78
Study 33734131 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 78
Study 33734131 — intervention group
Group type: COMPARATOR
Intervention: Intracerebral mass (ICM) positivity
Number of subjects: 78
Study 33734131 — intervention group
Group type: COMPARATOR
Intervention: >4 organs involved at diagnosis
Number of subjects: 78
Study 36134382 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Safety Huddles
Number of subjects: 0
Study 33250404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB)
Number of subjects: 382
Study 33250404 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 382
Study 33250404 — intervention group
Group type: EXPERIMENTAL
Intervention: RAKI (developed)
Number of subjects: 382
Study 36012027 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly food education sessions based on the Transtheoretical model
Number of subjects: 0
Study 36012027 — intervention group
Group type: COMPARATOR
Intervention: 3 general educational sessions on food and health
Number of subjects: 0
Study 33929094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acute HIV infection (AHI) screening, contract partner notification, and social contact referral
Number of subjects: 1230
Study 33929094 — intervention group
Group type: COMPARATOR
Intervention: Malawian standard of care: serial rapid serological HIV tests and passive partner referral
Number of subjects: 1230
Study 35743686 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (ISWT)
Number of subjects: 29
Study 35743686 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walking Test (6MWT)
Number of subjects: 29
Study 35743686 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ISWT and 6MWT
Number of subjects: 29
Study 33029913 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical Vibroacupuncture (MVA)
Number of subjects: 13
Study 33029913 — intervention group
Group type: COMPARATOR
Intervention: Sham Procedure (SP)
Number of subjects: 13
Study 33029913 — intervention group
Group type: COMPARATOR
Intervention: Vibroacupuncture (VA)
Number of subjects: 13
Study 33125517 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil infusion
Number of subjects: 60
Study 33125517 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (Control)
Number of subjects: 60
Study 35782066 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine physical therapy with neuromobilization (Group 2)
Number of subjects: 66
Study 35782066 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy without neuromobilization (Group 1)
Number of subjects: 66
Study 34571629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling using heavy brilliant blue G (hBBG) staining
Number of subjects: 44
Study 34571629 — intervention group
Group type: COMPARATOR
Intervention: No staining (control group)
Number of subjects: 44
Study 34389984 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM intervention (universal family‐based substance use preventive intervention)
Number of subjects: 216
Study 34389984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 33543589 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-access alcohol seeking
Number of subjects: 40
Study 33543589 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive-ratio seeking
Number of subjects: 40
Study 33543589 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of alcoholism, venturesomeness traits, and disinhibition traits
Number of subjects: 40
Study 33543589 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of alcoholism, disinhibition traits, and recent drinking history
Number of subjects: 40
Study 35247530 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 507
Study 35247530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 507
Study 32769416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Interdisciplinary Pain Treatment (IIPT)
Number of subjects: 182
Study 32769416 — intervention group
Group type: COMPARATOR
Intervention: Multimodal Treatment (MMT)
Number of subjects: 182
Study 35427469 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD)
Number of subjects: 354
Study 35427469 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD)
Number of subjects: 354
Study 35427469 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD) in high-risk patients
Number of subjects: 354
Study 35427469 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD) in high-risk patients
Number of subjects: 354
Study 33461621 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl
Number of subjects: 0
Study 33461621 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl on mud walls
Number of subjects: 0
Study 32003122 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury (EI)
Number of subjects: 200
Study 32003122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 34314816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of education on self-management and ergonomic principles, a prefabricated neoprene splint, hand exercises, and diclofenac sodium gel
Number of subjects: 204
Study 34314816 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 204
Study 34464780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3OHB infusion
Number of subjects: 8
Study 34464780 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 32187788 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pneumatic compression device (APCD), at-home Flexitouch head and neck APCD, used for at least 30 minutes daily
Number of subjects: 205
Study 34480861 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily for up to 14 days)
Number of subjects: 1525
Study 34480861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1525
Study 32321490 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-polishing with trehalose powder
Number of subjects: 10
Study 32321490 — intervention group
Group type: COMPARATOR
Intervention: Sonic scaling
Number of subjects: 10
Study 34156755 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella
Number of subjects: 54480
Study 34156755 — intervention group
Group type: COMPARATOR
Intervention: IABP
Number of subjects: 54480
Study 33853997 — intervention group
Group type: EXPERIMENTAL
Intervention: Various novel therapeutic interventions
Number of subjects: 0
Study 33853997 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for treatment of myocardial infarction
Number of subjects: 0
Study 33853997 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy, lipid lowering, anti-diabetes, anti-obesity, heart failure treatments
Number of subjects: 0
Study 35122105 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 2099
Study 35122105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2099
Study 33530298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (protein-rich beverage powder fortified with calcium 600 mg, vitamin D 400 IU, and vitamin K 55 mcg per daily serving)
Number of subjects: 0
Study 33530298 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement (low-protein non-fortified isocaloric beverage powder)
Number of subjects: 0
Study 33764277 — intervention group
Group type: EXPERIMENTAL
Intervention: EPMHSS and counseling intervention
Number of subjects: 74
Study 33764277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 36435274 — intervention group
Group type: EXPERIMENTAL
Intervention: WIfI stage 4
Number of subjects: 1568
Study 36435274 — intervention group
Group type: COMPARATOR
Intervention: WIfI stages 1-3
Number of subjects: 1568
Study 34542577 — intervention group
Group type: EXPERIMENTAL
Intervention: iBASIS‐VIPP preemptive intervention plus usual care
Number of subjects: 104
Study 34542577 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 104
Study 35270660 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week motor intervention, 60 min per session, twice per week
Number of subjects: 22
Study 35270660 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 34506246 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 300
Study 34506246 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 300
Study 34542061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk side flexion exercises
Number of subjects: 14
Study 34542061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk draw-in exercises
Number of subjects: 14
Study 34282598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and Verapamil
Number of subjects: 40
Study 34282598 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril alone
Number of subjects: 40
Study 32415471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program (three times a week for eight weeks)
Number of subjects: 28
Study 35486073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) with 30-g and 60-g donor feces
Number of subjects: 164
Study 35486073 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (own feces)
Number of subjects: 164
Study 35486073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 164
Study 33993104 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous telepsychiatry (ATP)
Number of subjects: 184
Study 33993104 — intervention group
Group type: COMPARATOR
Intervention: Synchronous telepsychiatry (STP)
Number of subjects: 184
Study 35670873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg BID for 1 week, followed by gefapixant 600 mg BID for 2 weeks
Number of subjects: 36
Study 35670873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32924787 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy in elderly patients
Number of subjects: 163
Study 34371102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for substance use (up to 12 sessions over 14 weeks)
Number of subjects: 95
Study 34371102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy targeting depression (CBT-D)
Number of subjects: 95
Study 34371102 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 95
Study 34371102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for substance use
Number of subjects: 95
Study 34371102 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinalysis for cannabis use
Number of subjects: 95
Study 35854374 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED therapy
Number of subjects: 39
Study 35854374 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared LED therapy
Number of subjects: 39
Study 35854374 — intervention group
Group type: COMPARATOR
Intervention: Simulated photobiomodulation (placebo)
Number of subjects: 39
Study 33624327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory training program
Number of subjects: 91
Study 33624327 — intervention group
Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 91
Study 35763041 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT+sorafenib
Number of subjects: 45
Study 35763041 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 45
Study 33795167 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 88% sucrose (SUC)
Number of subjects: 72
Study 33795167 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of placebo (PLA)
Number of subjects: 72
Study 36068213 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (daunorubicin and ara-C)
Number of subjects: 149
Study 36068213 — intervention group
Group type: COMPARATOR
Intervention: ADE (ara-C, daunorubicin, and etoposide)
Number of subjects: 149
Study 34238628 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (I-CBT)
Number of subjects: 111
Study 34238628 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 111
Study 36471424 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit feedback and tailored educational and peer support cointervention
Number of subjects: 70
Study 36471424 — intervention group
Group type: COMPARATOR
Intervention: Audit feedback alone (control)
Number of subjects: 70
Study 33173385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiation (CRT)
Number of subjects: 226
Study 33173385 — intervention group
Group type: COMPARATOR
Intervention: Concurrent CRT (CCRT)
Number of subjects: 226
Study 33173385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour size and nodal involvement
Number of subjects: 226
Study 33173385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRT
Number of subjects: 226
Study 33683572 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 84
Study 33683572 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 84
Study 33053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5‐10 mg once per day, orally; n=49)
Number of subjects: 97
Study 33053113 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 97
Study 35942814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tiotropium bromide 5 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 27)
Number of subjects: 80
Study 35942814 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily fluticasone propionate 125 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 25)
Number of subjects: 80
Study 35942814 — intervention group
Group type: COMPARATOR
Intervention: As-needed albuterol sulfate 0.2 mg alone (n = 28)
Number of subjects: 80
Study 33951448 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) as a first-line treatment
Number of subjects: 771
Study 33951448 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment as a first-line treatment
Number of subjects: 771
Study 32552731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68
Study 32552731 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 68
Study 35552375 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ligation procedure for prolapsed haemorrhoids (MLPPH)
Number of subjects: 133
Study 35552375 — intervention group
Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy (SH)
Number of subjects: 133
Study 32178692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omega-3 and plant sterols
Number of subjects: 0
Study 32178692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34159762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enarodustat 20 mg
Number of subjects: 54
Study 34159762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enarodustat 150 mg (supratherapeutic dose)
Number of subjects: 54
Study 34159762 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-M2 (metabolite of enarodustat)
Number of subjects: 54
Study 34159762 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control, 400 mg)
Number of subjects: 54
Study 33028396 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthohumol 24 mg/day for 8 weeks
Number of subjects: 0
Study 33028396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33028396 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Number of subjects: 0
Study 35501471 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain prevention interventions
Number of subjects: 0
Study 34304146 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (twice-daily, 20-min, 2-mA for 5 days)
Number of subjects: 90
Study 34304146 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 90
Study 35733213 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose denosumab 60 mg subcutaneous injection
Number of subjects: 0
Study 35733213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32686234 — intervention group
Group type: COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42
Study 32686234 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42
Study 32686234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GBR and CTG
Number of subjects: 42
Study 35439647 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led surveillance
Number of subjects: 0
Study 35439647 — intervention group
Group type: COMPARATOR
Intervention: Clinician-led surveillance
Number of subjects: 0
Study 34228066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine (1.5-mg capsules taken 6 times daily for 25 days)
Number of subjects: 1452
Study 34228066 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (0.5-mg tablets titrated to 1 mg twice daily for 84 days)
Number of subjects: 1452
Study 34228066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 1452
Study 34228066 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 1452
Study 32638031 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-sucrose octasulfate
Number of subjects: 117
Study 35352968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal care attendance
Number of subjects: 123
Study 35352968 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum visit attendance
Number of subjects: 123
Study 33674988 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg/day for 12 weeks
Number of subjects: 64
Study 33674988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32264947 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding meditation audio
Number of subjects: 0
Study 32264947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 34386838 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH
Number of subjects: 506
Study 34386838 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH+FAMS
Number of subjects: 506
Study 34386838 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 506
Study 33448199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact group (double bundles of PCL retained)
Number of subjects: 200
Study 33448199 — intervention group
Group type: COMPARATOR
Intervention: Partial group (partial resection of the anterior lateral bundle of PCL)
Number of subjects: 200
Study 33448199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact group
Number of subjects: 200
Study 33448199 — intervention group
Group type: COMPARATOR
Intervention: Partial group
Number of subjects: 200
Study 32790486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelnac
Number of subjects: 71
Study 32790486 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra
Number of subjects: 71
Study 35330427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 10
Study 35330427 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 10
Study 32333877 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg cinacalcet per day plus 60 mg denosumab subcutaneously every 6 months (combination group)
Number of subjects: 285
Study 32333877 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg denosumab subcutaneously every 6 months (denosumab group)
Number of subjects: 285
Study 32333877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 285
Study 35415779 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness education
Number of subjects: 0
Study 35415779 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 35415779 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 0
Study 34722783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfredson group (AG)
Number of subjects: 40
Study 34722783 — intervention group
Group type: EXPERIMENTAL
Intervention: Silbernagel group (SG)
Number of subjects: 40
Study 35187164 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality task for ALS patients, duration 10 minutes, sitting position.
Number of subjects: 0